ABBV — Abbvie Cashflow Statement
0.000.00%
Last trade - 00:00- $362.60bn
- $424.88bn
- $61.16bn
Annual cashflow statement for Abbvie, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 11,549 | 11,845 | 4,873 | 4,286 | 4,233 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4,927 | 6,820 | 9,344 | 10,365 | 9,512 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,322 | -258 | 2,813 | -2,782 | -2,362 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 22,777 | 24,943 | 22,839 | 18,806 | 19,030 |
| Capital Expenditures | -787 | -695 | -777 | -974 | -1,214 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1,557 | 72 | -1,232 | -19,846 | -5,429 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,344 | -623 | -2,009 | -20,820 | -6,643 |
| Financing Cash Flow Items | -674 | -1,102 | -742 | -42 | 45 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -19,039 | -24,803 | -17,222 | -5,211 | -12,724 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,297 | -545 | 3,613 | -7,290 | -295 |